183 related articles for article (PubMed ID: 1804384)
1. Evaluation of second-look laparotomy for ovarian cancer: second-look vs. serum CA125.
Liu L; Hong W; Hou Y; Yao Z; Wu A; Wang X
Chin Med Sci J; 1991 Jun; 6(2):96-9. PubMed ID: 1804384
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
3. [Second-look laparotomy in epithelial ovarian cancer: an evaluation of 23 cases].
Liu LY
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):77-9, 123. PubMed ID: 2364794
[TBL] [Abstract][Full Text] [Related]
4. CA125 in peritoneal fluid of ovarian cancer patients.
Vergote IB; Onsrud M; Børmer OP; Sert BM; Moen M
Gynecol Oncol; 1992 Feb; 44(2):161-5. PubMed ID: 1544593
[TBL] [Abstract][Full Text] [Related]
5. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
Berek JS; Hacker NF; Lagasse LD; Poth T; Resnick B; Nieberg RK
Obstet Gynecol; 1984 Aug; 64(2):207-12. PubMed ID: 6539884
[TBL] [Abstract][Full Text] [Related]
6. Use of second-look laparotomy in the management of patients with ovarian epithelial malignancies.
Podczaski ES; Stevens CW; Manetta A; Whitney CW; Larson JE; Mortel R
Gynecol Oncol; 1987 Oct; 28(2):205-14. PubMed ID: 3666578
[TBL] [Abstract][Full Text] [Related]
7. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
8. [Serum CA 125 values and histologic findings at the time of second-look laparotomy in ovarian cancer].
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Geburtshilfe Frauenheilkd; 1988 May; 48(5):331-3. PubMed ID: 3165078
[TBL] [Abstract][Full Text] [Related]
9. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Jun; 37(3):319-22. PubMed ID: 2190870
[TBL] [Abstract][Full Text] [Related]
10. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
Obermair A; Sevelda P
Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
[TBL] [Abstract][Full Text] [Related]
11. Use of CA 125 to monitor patients with ovarian epithelial carcinomas.
Podczaski E; Whitney C; Manetta A; Larson JE; Kirk J; Stevens CW; Lyter J; Mortel R
Gynecol Oncol; 1989 May; 33(2):193-7. PubMed ID: 2703180
[TBL] [Abstract][Full Text] [Related]
12. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
McGuckin MA; Layton GT; Bailey MJ; Hurst T; Khoo SK; Ward BG
Gynecol Oncol; 1990 May; 37(2):165-71. PubMed ID: 1693126
[TBL] [Abstract][Full Text] [Related]
14. Second-look laparotomy after chemotherapy in the management of ovarian malignancy.
Smirz LR; Stehman FB; Ulbright TM; Sutton GP; Ehrlich CE
Am J Obstet Gynecol; 1985 Jul; 152(6 Pt 1):661-8. PubMed ID: 4040706
[TBL] [Abstract][Full Text] [Related]
15. CA-125 in gynecological malignancies.
Meier W; Stieber P; Fateh-Moghadam A; Eiermann W; Hepp H
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):713-7. PubMed ID: 2443359
[TBL] [Abstract][Full Text] [Related]
16. The trend of serum CA125 levels during the first three courses of chemotherapy as a predictor of second-look findings in patients with ovarian carcinoma.
Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Mariani G; Bianchi R; Fioretti P
J Nucl Med Allied Sci; 1989; 33(3):243-6. PubMed ID: 2778499
[TBL] [Abstract][Full Text] [Related]
17. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
18. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
Patsner B; Orr JW; Mann WJ; Taylor PT; Partridge E; Allmen T
Gynecol Oncol; 1990 Sep; 38(3):373-6. PubMed ID: 2227551
[TBL] [Abstract][Full Text] [Related]
19. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer.
Prayer L; Kainz C; Kramer J; Stiglbauer R; Schurawitzki H; Baldt M; Schima W; Poelzleitner D; Reinthaller A; Koelbl H
J Comput Assist Tomogr; 1993; 17(4):626-32. PubMed ID: 8331235
[TBL] [Abstract][Full Text] [Related]
20. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.
Alvarez Secord A; Sayer R; Snyder SA; Broadwater G; Rodriguez GC; Berchuck A; Blackwell K
Gynecol Oncol; 2004 Jul; 94(1):74-9. PubMed ID: 15262122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
